Integrated Analysis of Altered lncRNA, circRNA, microRNA, and mRNA Expression in Hepatocellular Carcinoma Carrying TERT Promoter Mutations
Haibin Zhang,Xiaolu Zhang,Jingya Yu
DOI: https://doi.org/10.2147/JHC.S385026
2022-11-30
Journal of Hepatocellular Carcinoma
Abstract:Haibin Zhang, 1 Xiaolu Zhang, 1 Jingya Yu 2 1 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, People's Republic of China; 2 Department of Diagnostics, Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, People's Republic of China Correspondence: Jingya Yu, Department of Diagnostics, Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, People's Republic of China, Tel +8653188382085, Email Background and Objectives: Telomerase reverse transcriptase (TERT) promoter mutations are one of the most common mutations responsible for the development of hepatocellular carcinoma (HCC). Noncoding RNAs (ncRNAs) play a regulatory role in different cancers through the long noncoding RNA (lncRNA)/circular RNA (circRNA)-microRNA (miRNA)-mRNA axis. The aim of the study was to explore the influence of TERT promoter mutations on the ncRNA regulatory network in HCC. Methods: Four tumor samples with a wildtype TERT promoter and four tumor samples with TERT promoter mutations (sequencing cohort) were collected from HCC patients for high-throughput next-generation sequencing. Selected ncRNAs and mRNAs were validated by qPCR in 15 HCC tumors with a wildtype TERT promoter and seven HCC tumors with TERT promoter mutations (validation cohort, including the sequencing cohort). Results: In the mutant TERT promoter group, 536 lncRNAs, 21 circRNAs, 41 miRNAs, and 266 mRNAs were significantly up-regulated, while 1745 lncRNAs, 23 circRNAs, 32 miRNAs, and 1117 mRNAs were significantly down-regulated ( P < 0.05) compared with the findings in wildtype group. AL360169.3-201, LINC02672-203, hsa_circ_0021412, hsa-miR-29b-1-5p, hsa-miR-4699-5p, hsa-miR-199a-5p, REG3A, SFRP5, and GSTM1 were verified at the RNA expression level to validate the sequencing results. A differentially expressed lncRNA/circRNA-miRNA-mRNA network was constructed to explore the effects of TERT promoter mutations on ncRNA regulation. Two ncRNA regulatory axes associated with TERT promoter mutations (hsa_circ_0003154/hsa_circ_0008952/IGLL5-AS1/LINC576/LINC575–hsa-miR-1260b –CLPTM1L/GSTM1 and hsa_circ_0031584/LINC2101–hsa-miR-214-3p–CD151) had carcinogenic potential. Conclusion: This study provides novel insights into the role of TERT promoter mutations on ncRNAs regulatory network in HCC progression. Keywords: hepatocellular carcinoma, TERT promoter mutations, lncRNA, circRNA, microRNA Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. In 2020, primary liver malignancy was the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. 1,2 The incidence rate is extremely high in Eastern Asia, and China is one of the most high-risk HCC areas. 2 Multiple risk factors are responsible for the development of HCC, including chronic hepatitis B or C infection, cigarette smoking, and alcohol abuse. In addition, several mutations are associated with HCC, including telomerase reverse transcriptase (TERT) promoter mutation, which is one of the most-studied mutations in HCC. 3 Telomerase is a cellular ribonucleoprotein enzyme. It promotes cell proliferation by elongating the telomere. TERT is a subunit of telomerase that is responsible for its catalytic activity. 4 Typically, its expression is tightly limited in most normal cells, but up-regulated in multiple cancers. 5 TERT expression can be regulated at both the transcription and posttranslation levels. At the transcription level, some cancer-associated TERT promoter mutations function by generating de novo transcription-factor-binding sites. Two major TERT promoter mutations are −124C/T and −146C/T, which are named C228T and C250T, respectively. These two mutations generate putative ETS transcription-factor-binding sites (TTCC), thereby activating TERT transcription. 6,7 TERT promoter mutations have been identified in several human cancers, including bladder cancer, glioblastoma, and melanoma. 8,9 HCC has a high mutation frequency. Up to 60% of HCC patients carry TERT promoter mutations. 10,11 However, in some cases, TERT promoter mutations are not accompanied by a high TERT expression. 12 No difference in TERT immunohistochemical expression levels was observed between skin tumors with and without TERT promoter mutations. 13 Moreover, there was no significant association between TERT mutation and expression in bladder cancer. 14 Furthermore, it was also reported that the TERT promoter mutation st -Abstract Truncated-
oncology